Home » Stocks » ATHA

Athira Pharma, Inc. (ATHA)

Stock Price: $18.48 USD 0.43 (2.38%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 670.02M
Revenue (ttm) n/a
Net Income (ttm) -19.96M
Shares Out 37.12M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $18.48
Previous Close $18.05
Change ($) 0.43
Change (%) 2.38%
Day's Open 18.19
Day's Range 17.75 - 18.98
Day's Volume 109,996
52-Week Range 15.79 - 34.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Athira Pharma, Inc. (ATHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 weeks ago - Zacks Investment Research

BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...

2 weeks ago - GlobeNewsWire

BOTHELL, Wash., April 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...

1 month ago - GlobeNewsWire

– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling patients –

1 month ago - GlobeNewsWire

BOTHELL, Wash., March 24, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...

1 month ago - GlobeNewsWire

BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...

1 month ago - GlobeNewsWire

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...

2 months ago - GlobeNewsWire

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...

Other stocks mentioned: ABIO, MTCR
2 months ago - GuruFocus

BOTHELL, Wash., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neurona...

2 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: INTC, TDY, AA, ARMP, FAST, FCEL, FRG ...
3 months ago - Benzinga

The clinical-stage biopharma company announced the pricing of a public stock offering.

3 months ago - The Motley Fool

BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neurona...

3 months ago - GlobeNewsWire

BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neurona...

3 months ago - GlobeNewsWire

Athira is a recent IPO with early but interesting data in AD. They will provide data from a potentially pivotal phase 2/3 trial in end-2022.

3 months ago - Seeking Alpha

SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop n...

4 months ago - GlobeNewsWire

SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop n...

4 months ago - GlobeNewsWire

Seattle-based biotech company Athira Pharma announced a three-year grant totaling $15 million from the National Institute on Aging to support an upcoming clinical trial of a treatment that seeks to stop...

4 months ago - GeekWire

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop n...

4 months ago - GlobeNewsWire

SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop n...

5 months ago - GlobeNewsWire

 - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling 

5 months ago - GlobeNewsWire

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop n...

5 months ago - GlobeNewsWire

- Expert neuropsych iatric clinician to discuss the testing method and its correlation to clinical results

6 months ago - GlobeNewsWire

SEATTLE, Oct. 8, 2020 /PRNewswire/ -- Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton...

6 months ago - PRNewsWire

- Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to- moderate Alzheimer’s disease -

7 months ago - GlobeNewsWire

Andreas Halvorsen (Trades, Portfolio)'s Viking Global Investors recently participated in the initial public offering of biotech company Athira Pharma Inc. (NASDAQ:ATHA). According to GuruFocus Real-Time...

7 months ago - GuruFocus

SEATTLE, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal he...

7 months ago - GlobeNewsWire

More than 5 million Americans have Alzheimer’s disease, and the number is projected to rise to nearly 14 million by 2050.

7 months ago - GeekWire

Shares of Athira Pharma Inc. ATHA, +5.48% rallied in their public debut, as the first trade was 17.4% above the initial public offering price.

7 months ago - Market Watch

Athira Pharma Inc. ATHA, priced its initial public offering at $17 a share, the top end of its proposed price range.

7 months ago - Market Watch

Athira Pharma Inc. (NASDAQ: ATHA) on Thursday upsized its initial public offering plans over what it earlier reported in a filing with the Securities and Exchange Commission.

7 months ago - Benzinga

Athira Pharma will raise at least $204 million as the Seattle biotech startup becomes a public company on Friday.

7 months ago - GeekWire

SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal he...

7 months ago - GlobeNewsWire

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, inc... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ATHA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Athira Pharma stock is "Buy." The 12-month stock price forecast is 43.25, which is an increase of 134.04% from the latest price.

Price Target
$43.25
(134.04% upside)
Analyst Consensus: Buy